$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045933 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$18.88M
YoY Change		33.36%
Cost Of Revenue		$10.68M
YoY Change		38.56%
Gross Profit		$8.197M
YoY Change		27.15%
Gross Profit Margin		43.42%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$1.966M
YoY Change		-24.91%
% of Gross Profit		23.98%
Depreciation & Amortization		$227.4K
YoY Change		-30.52%
% of Gross Profit		2.77%
Operating Expenses		$4.712M
YoY Change		4.22%
Operating Profit		$3.485M
YoY Change		80.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$13.00M
YoY Change		179.16%
Pretax Income		-$9.519M
YoY Change		248.33%
Income Tax		$1.517M
% Of Pretax Income
Net Earnings		-$11.04M
YoY Change		-173.9%
Net Earnings / Revenue		-58.45%
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding	1.068B shares	1.068B shares
Diluted Shares Outstanding		1.068B shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$9.999M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$14.16M
Prepaid Expenses
Receivables		$21.44M
Other Receivables
Total Short-Term Assets		$45.29M
YoY Change		30.42%
LONG-TERM ASSETS
Property, Plant & Equipment		$10.18M
YoY Change		4.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$42.90M
YoY Change		19.21%
TOTAL ASSETS
Total Short-Term Assets		$45.29M
Total Long-Term Assets		$42.90M
Total Assets		$88.20M
YoY Change		24.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.983M
YoY Change		-45.05%
Accrued Expenses		$5.703M
YoY Change		-48.89%
Deferred Revenue		$12.22K
YoY Change		-8.33%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$12.85M
YoY Change		-32.63%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$28.08M
YoY Change		328.88%
TOTAL LIABILITIES
Total Short-Term Liabilities		$12.85M
Total Long-Term Liabilities		$28.08M
Total Liabilities		$40.93M
YoY Change		59.73%
SHAREHOLDERS EQUITY
Retained Earnings		-$126.8M
YoY Change		5.3%
Common Stock		$1.068M
YoY Change		5.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$306.8K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		$47.27M
YoY Change
Total Liabilities & Shareholders Equity		$88.20M
YoY Change		24.72%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$11.04M
YoY Change		-173.9%
Depreciation, Depletion And Amortization		$227.4K
YoY Change		-30.52%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4129621	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2273744	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52329	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42777	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2024Q3	us-gaap	Cash Cash	9554963	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21443555	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	130386	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	45293849	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10176587	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7241228	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2010440	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2089024	usd
CY2024Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	20843504	usd
CY2024Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	444124	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	99240	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	543364	usd
CY2024Q3	us-gaap	Assets Assets	88197996	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1983280	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5703464	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12222	usd
CY2024Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	125822	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	242058	usd
CY2024Q3	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	364551	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	422323	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12853720	usd
CY2024Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	780292	usd
CY2024Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	2295872	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1741240	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	21835656	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	28077256	usd
CY2024Q3	us-gaap	Liabilities Liabilities	40930976	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1068377	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173315207	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126809723	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	47267020	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88197996	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Registrant Name EntityRegistrantName	Elite Pharmaceuticals Inc /NV/
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1		usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
	ELTP	Finance Directors And Officers Insurance Premium FinanceDirectorsAndOfficersInsurancePremium		usd
	ELTP	Recognition Of Finance Lease Right Of Use Asset And Lease Liabilities Entered Into RecognitionOfFinanceLeaseRightOfUseAssetAndLeaseLiabilitiesEnteredInto		usd
CY2024Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2023Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2024Q3	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2024Q3	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees		usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent		usd
CY2024Q3	ELTP	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent		pure
	ELTP	Awarded Shares AwardedShares		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15697
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 Ludlow Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Northvale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	750-2646
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ELTP
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1068273108	shares
CY2024Q1	us-gaap	Cash Cash	7106262	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	261000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	236000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19453301	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	14164945	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12930464	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	524162	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	40014189	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16425248	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15906853	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10175293	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2079658	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2355201	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	22160895	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	432832	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	94240	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	527072	usd
CY2024Q1	us-gaap	Assets Assets	83653536	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2714306	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5301747	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2024Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	115822	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	180399	usd
CY2024Q1	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	312739	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	411418	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13049764	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5556	usd
CY2024Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	913203	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2366487	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1424196	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1480317	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1957383	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	6298008	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13020954	usd
CY2024Q1	us-gaap	Liabilities Liabilities	26070718	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068373108	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068373108	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068273108	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068273108	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1068377	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173210549	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116389267	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	57582818	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83653536	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18880345	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14157185	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37683408	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23137261	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	10682917	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	7710106	usd
	us-gaap	Cost Of Revenue CostOfRevenue	21011202	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11939627	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	8197428	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	6447079	usd
	us-gaap	Gross Profit GrossProfit	16672206	usd
	us-gaap	Gross Profit GrossProfit	11197634	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1966094	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2618349	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3761894	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1533208	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4242898	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3194912	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104658	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57777	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	420318	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	327240	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	846030	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	655522	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	4712485	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4521574	usd
	us-gaap	Operating Expenses OperatingExpenses	9323207	usd
	us-gaap	Operating Expenses OperatingExpenses	7670105	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3484943	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1925505	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	7348999	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	3527529	usd
CY2024Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-12754735	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2468350	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-15537648	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
CY2023Q3	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
CY2024Q3	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	255136	usd
CY2023Q3	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	130438	usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	505917	usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	249850	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5902	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7320	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11292	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10836	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	12000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13003969	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4658288	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16020273	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4963551	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9519026	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2732783	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8671274	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1436022	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1517203	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17667384	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1749182	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17512432	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-11036229	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10420456	usd
	us-gaap	Net Income Loss NetIncomeLoss	16076410	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1068273108	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019316919	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1068273108	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1016944870	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	57582818	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	615773	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52329	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	58250920	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-11036229	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52329	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	47267020	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42777	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	45094447	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	45094447	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10420456	usd
	us-gaap	Net Income Loss NetIncomeLoss	16076410	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	622947	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	655522	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	24584	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30798	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	266177	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11163	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	223088	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7089	usd
	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1	-121481	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-15537648	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1317391	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-17261347	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	104658	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	57777	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	655	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2014838	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7431310	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1234481	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5673668	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-587233	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-677224	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-731026	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1162183	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	401717	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4043722	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6667	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6668	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-205238	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12751	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4601307	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2945753	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	870972	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	900000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	125250	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1645722	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	130000	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	125000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	158179	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	207413	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	97275	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-495592	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3777725	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2459993	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	831972	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7539094	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9999087	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9076653	usd
	us-gaap	Interest Paid Net InterestPaidNet	367135	usd
	us-gaap	Interest Paid Net InterestPaidNet	119412	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	496262	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	127522	usd
	ELTP	Finance Directors And Officers Insurance Premium FinanceDirectorsAndOfficersInsurancePremium	198457	usd
	ELTP	Recognition Of Finance Lease Right Of Use Asset And Lease Liabilities Entered Into RecognitionOfFinanceLeaseRightOfUseAssetAndLeaseLiabilitiesEnteredInto	153870	usd
CY2024Q3	us-gaap	Cash Cash	9554963	usd
CY2023Q3	us-gaap	Cash Cash	8653903	usd
CY2024Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	444124	usd
CY2023Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	422750	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9999087	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9076653	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_z3eW9bZISQm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z2qqp5JDeaE">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as reported amounts of revenues and expenses during the reporting period. Such management estimates and assumptions include, but are not limited to, standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations, the period of benefit for deferred commissions, valuation of intangible assets, the useful life of property and equipment and identifiable intangible assets, stock-based compensation expense and income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	444124	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	432832	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	900000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7241228	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
CY2024	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	0	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11036229	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14934601	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10420456	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16076410	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11036229	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14934601	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10420456	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	16076410	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2023Q3	us-gaap	Dilutive Securities DilutiveSecurities	5401838	usd
	us-gaap	Dilutive Securities DilutiveSecurities	3029789	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1068273108	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019316919	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1068273108	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1016944870	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	6298008	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-15537648	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	21835656	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3179428	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4620746	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4465970	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1793421	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1804426	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	7750778	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	6660068	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	14164945	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12930464	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26601835	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26082146	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16425248	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15906853	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10176587	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10175293	usd
CY2024Q3	us-gaap	Depreciation Depreciation	227356	usd
CY2023Q3	us-gaap	Depreciation Depreciation	327240	usd
	us-gaap	Depreciation Depreciation	622947	usd
	us-gaap	Depreciation Depreciation	655522	usd
CY2024Q3	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit	4008074	usd
CY2024Q1	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit	3684587	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	559248	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	206225	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	420856	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	485327	usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	125000	usd
CY2024Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	90000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	80000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2024Q3	ELTP	Accrued Director Dues AccruedDirectorDues	22500	usd
CY2024Q1	ELTP	Accrued Director Dues AccruedDirectorDues	22500	usd
CY2024Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	20000	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	172424	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	315362	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	668108	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5703464	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5301747	usd
CY2024Q3	ELTP	Mortgage Loan Payable MortgageLoanPayable	2377263	usd
CY2024Q1	ELTP	Mortgage Loan Payable MortgageLoanPayable	2418426	usd
CY2024Q3	us-gaap	Loans Payable LoansPayable	160667	usd
CY2024Q1	us-gaap	Loans Payable LoansPayable	128460	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	242058	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	180399	usd
CY2024Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	2295872	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2366487	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	33135	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	93832	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	68017	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	171070	usd
	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	(i) ownership of the underlying asset transfers to the Company by the end of the lease term; (ii) the lease contains an option to purchase the underlying asset that the Company is reasonably expected to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of lease payments and any residual value guaranteed by the Company equals or exceeds substantially all of the fair value of the underlying asset; or (v) the underlying asset is of a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2010440	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2079658	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2089024	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2355201	usd
CY2024Q3	ELTP	Lease Assets LeaseAssets	4099464	usd
CY2024Q1	ELTP	Lease Assets LeaseAssets	4434859	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	364551	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	312739	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	422323	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	411418	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1424196	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1480317	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1741240	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1957383	usd
CY2024Q3	ELTP	Lease Liabilities LeaseLiabilities	3952310	usd
CY2024Q1	ELTP	Lease Liabilities LeaseLiabilities	4161857	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	310075	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due In Next Rolling Twelve Months FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths	259468	usd
CY2024Q3	ELTP	Lease Liability Payments Due Next Twelve Months LeaseLiabilityPaymentsDueNextTwelveMonths	569543	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	623565	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	517241	usd
CY2024Q3	ELTP	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	1140806	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	637050	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	484151	usd
CY2024Q3	ELTP	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	1121201	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	650871	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	479337	usd
CY2024Q3	ELTP	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	1130208	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	440159	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	438045	usd
CY2024Q3	ELTP	Lease Liability Payments Due Year Five LeaseLiabilityPaymentsDueYearFive	878204	usd
CY2024Q3	ELTP	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	13740	usd
CY2024Q3	ELTP	Lease Liability Payments Due After Year Four LeaseLiabilityPaymentsDueAfterYearFour	13740	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	498157	usd
CY2024Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	403235	usd
CY2024Q3	ELTP	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	901392	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2163563	usd
CY2024Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	1788747	usd
CY2024Q3	ELTP	Lease Liabilities LeaseLiabilities	3952310	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2024Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2024Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.095	pure
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y7M6D
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y1M6D
CY2023Q1	ELTP	Stock Based Compensation StockBasedCompensation	4278333	usd
	ELTP	Increase Decrease In Stock Based Liabilities IncreaseDecreaseInStockBasedLiabilities	1973905	usd
CY2023Q3	ELTP	Stock Based Compensation StockBasedCompensation	6252238	usd
CY2024Q3	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	12730000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15730000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1626748	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	60000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.09
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15670000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5267752	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6323334	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.05
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P8Y
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2127078	usd
CY2024Q3	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.39
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	333263	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M23D
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1749182	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17512432	usd
CY2024Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1517203	usd
CY2023Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17667384	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-045933-index-headers.html	Edgar Link	pending
0001493152-24-045933-index.html	Edgar Link	pending
0001493152-24-045933.txt	Edgar Link	pending
0001493152-24-045933-xbrl.zip	Edgar Link	pending
eltp-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
eltp-20240930_def.xml	Edgar Link	unprocessable
eltp-20240930_lab.xml	Edgar Link	unprocessable
eltp-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
eltp-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q4 Form 10-Q Financial Statement

#000149315224045933 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q4 Form 10-Q Financial Statement

#000149315224045933 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp